mRNA Revolution: eXmoor case study

eXmoor logo.jpg 1

eXmoor is a leading technical and strategic consultancy specialising in cell and gene therapies (ATMPs) and biopharmaceuticals. In this case study, the BIA's report mRNA Revolution: A new generation of medicine explores eXmoor's biomanufacturing offerings, including its facilities and expertise and its commercialisation lab facilities in Bristol. 

What does the company do?

eXmoor is a one-stop cell and gene therapy CDMO (contract development and manufacturing organisation), accelerating the manufacturing journey from research to patients. The company has grown over the last 19 years from supporting clients through consultancy for capital and technical projects and now offers in-house process development and GMP manufacturing. Phase 1 of eXmoor’s new purpose-built 65,000 ft2 facility includes four clean rooms, a fill and finish suite and a range of laboratories for process development, analytical development and quality control. 

eXmoor-Rapid RNA production.png


In August 2023 eXmoor formed a global partnership with Kincell Bio, a US-based CDMO that seamlessly brings together both companies’ capabilities, giving customers the opportunity to access a global development and manufacturing footprint in combination with a boutique customer-focused offering.

How will RNA be used?

The COVID-19 pandemic highlighted the significant benefits of mRNA-based vaccines, helping to accelerate the applications of this technology beyond just infectious diseases to other areas such as enzyme replacement and oncology. This has resulted in increased demand for mRNA manufacturing capacity. 

What are your challenges?

mRNA manufacture has unique challenges, and some learning is better transferred from skills developed in cell and gene therapy manufacture rather than classic biologics. eXmoor is uniquely positioned to help with additional capacity and specialist expertise.

Normally, as the scale of a biomanufacturing process increases the price per dose is reduced. But with RNA, driven by the high raw material costs, scale-up results in significant financial risk but only a limited reduction in the price per dose. Vaccine manufacture requires larger batch sizes so process development is likely to focus on efficient use and cost reduction of raw material, as this will have the biggest impact on the price per dose. But not all applications of mRNA need large-scale manufacture and are more sensitive to price per batch than price per dose. 

The high raw material cost used to manufacture mRNA significantly impacts the distribution of costs when working at larger IVT volume as shown below.

What does the future look like for eXmoor?

To support the additional mRNA manufacturing requirements, eXmoor is expanding its portfolio to include an end-to-end service for the manufacture of early-stage mRNA products and therapeutics focusing on flexible scale, rapid turn around and responsive material supply. 

eXmoor’s approach is designed to meet the needs of customers requiring smaller batch sizes and will target IVT scales of up to 0.5l. 




More news and updates 

CEO Update - 27 November 2023

Last week felt like an important milestone for the UK life science sector. As I sat in the Life Science Council in No 10 Downing Street with new Government Ministers, leaders of public institutions like the MHRA and global CEOs, I reflected that no other country in the world is putting together a working collaborative life science group like this.

bioProcessUK: The role of candidate screening and feasibility studies

Ian Goodwin, Director of CMC Program Design in Advanced Therapies (covering Cell and Gene Therapy services) at FUJIFILM Diosynth Biotechnologies explores the benefits of candidate and feasibility studies to AAV production.

Autumn Statement 2023 analysis

The Chancellor has delivered a comprehensive package of investment and support for the UK life sciences industry in his Autumn Statement. In this blog, Dr Martin Turner, Head of Policy and Public Affairs at BIA shares his reflections on key announcements.

Member spotlight: meet the Bio-Based and Biodegradable Industries Association

The Bio-Based and Biodegradable Industries Association (BBIA) and The BioIndustry Association (BIA) enter a mutual membership agreement to strengthen collaboration and support each other's work and member communities.

Bioprocessing: Unraveling the future by examining the past

Over the past two decades, the landscape of biopharmaceuticals in the UK has undergone a significant transformation.

CEO Update - 20 November 2023

London Life Sciences Week last week had an amazing buzz. I think there were more Americans in life science over for one week than I’ve ever experienced – centred on the Jefferies Healthcare Conference. At the same time, London was also full of Europeans at events like the Scrip Awards, where Jeremy Levin received the Lifetime Achievement Award and gave an impactful speech. The connectivity was immense - with a massive range of events that were really vibrant, diverse and inclusive.

London Life Sciences Week: connecting the global biotech community

London Life Sciences Week united the global biotech community for a dynamic week of networking and dealmaking. The BIA representatives were out and about throughout the week, networking with members and stakeholders. In this blog, Steve Bates OBE, CEO of BioIndustry Association, summarises insights based on the BIA team's first-hand experience.

ChilliPharm Data-driven insights: How digital media can help clinical trials succeed

Unleashing the potential of digital media in clinical trials: compliance by design

Future of UK Regulation Conference 2023: Novel technologies

BIA Future of UK Regulation Conference 2023: Novel technologies

mRNA Revolution: eXmoor case study

In this case study, the BIA's report mRNA Revolution: A new generation of medicine explores eXmoor's biomanufacturing offerings, including its facilities and expertise and its commercialisation lab facilities in Bristol. 


More within